With the recent FDA announcement regarding a one-year
delay in enforcement of the Compliance Policy for ‘Product
Identified Requirements Under the Drug Supply Chain
Security Act’ (DSCSA), many are left asking what this actually
means for the wider pharmaceutical industry or for their
own company’s initiatives. While the FDA communication
specifically indicates a delay in enforcement, it is clear there
is no delay of the law itself; a telling signal to the industry
that this serialisation challenge is real, affirms Justin
Schroeder, Senior Executive Director, Global Marketing &
Design at PCI Pharma Services.